Rhythm Pharmaceuticals, Inc. (RYTM) Financial Statements
Rhythm Pharmaceuticals, Inc. (RYTM) reported trailing twelve-month revenue of $239.9M (up 53.5% year on year) and net income of -$205.3M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$106.3M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
RYTMRhythm Pharmaceuticals, Inc.Follow RYTM — free
—
Price chart with a free account
- Market cap
- 6.1B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 3 Nov, in 10 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Revenue | 3.2 | 23.6 | 77.4 | 130.1 | 189.8 | 239.9 | |
| Gross profit | 2.6 | 21.5 | 68.1 | 116.8 | 170.3 | 213.5 | |
| Research & development | 104.1 | 108.6 | 135.0 | 238.0 | 167.3 | 173.2 | |
| Operating income | -170.1 | -179.2 | -184.4 | -265.5 | -192.0 | -200.6 | |
| Pre-tax income | — | — | -184.1 | -260.3 | -196.0 | -204.3 | |
| Income tax | — | — | 0.6 | 0.3 | 0.5 | 1.1 | |
| Net income | -69.6 | -181.1 | -184.7 | -260.6 | -196.5 | -205.3 | |
| Diluted EPS ($) | -1.40 | -3.47 | -3.20 | -4.34 | -3.11 | -3.11 | |
| Diluted shares (mn) | 49.6 | 52.1 | 57.7 | 61.0 | 65.0 | — |
USD millions · SEC XBRL
Rhythm Pharmaceuticals, Inc. — questions
- What is Rhythm Pharmaceuticals, Inc.'s revenue?
- $239.9M over the twelve months to 2026-06-30, up 53.5% year on year, from its 10-Q and 10-K filings.
- What is Rhythm Pharmaceuticals, Inc.'s net income?
- -$205.3M over the twelve months to 2026-06-30.
- What is Rhythm Pharmaceuticals, Inc.'s free cash flow?
- -$106.3M over the twelve months to 2026-06-30.
- What are Rhythm Pharmaceuticals, Inc.'s diluted earnings per share?
- $-3.11 over the twelve months to 2026-06-30.
Every figure on this page comes from Rhythm Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.